The US District Court for the District of Columbia has blocked the Aetna-Humana merger on the grounds it is anticompetitive.
The US District Court for the District of Columbia has blocked the Aetna-Humana merger. According to the decision, the efficiencies gained through the merger would not be enough “to mitigate the anticompetitive effects for consumers in the challenged markets.”
In July 2016, the Department of Justice (DOJ) filed an antitrust lawsuit to prevent both the Aetna-Humana merger and the Anthem-Cigna merger. The DOJ had been concerned that the 2 mergers, which would reduce the market from 5 big insurers to just 3, would lessen competition for individual Medicare Advantage plans and for insurance sold on the individual exchanges. After hearing arguments and reviewing the evidence, the court agrees.
Even the plan to save the merger through Aetna and Humana selling off certain Medicare Advantage assets to Molina Healthcare was not enough to appease the court.
According to the court's decision, new entrants into the market would not be sufficient to replace the competition lost by the merger. In the analysis most favorable to the defendants, there was only a 25.5% chance new entrants would make up for the lost competition, and that number could drop as low as 10%.
"So, even under the most generous of the plausible calculations the median county has a 13.3% chance of experiencing any entry, and a 25.5% chance that this new entry will be sufficient to replace the lost competition," US District Judge John D. Bates, wrote. "There is therefore a relatively small chance overall of replacing the competition lost by the proposed merger."
Aetna's spokesman, TJ Crawford, told Bloomberg that the company is reviewing the opinion and will consider appealing.
More on this story as it develops.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Early Involvement Critical in Treating Immunotherapy-Induced Overlap Syndrome
April 19th 2024A series of case studies reveals the importance of early diagnosis and involvement of special teams of clinicians when dealing with potential cases of overlap syndrome, which encompasses myocarditis, myasthenia gravis, and immune checkpoint inhibitor–related myositis.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen